Companies /Healthcare

Guardant Health Inc

NASDAQ: GH Diagnostics & Research
$145.83
▲ $0.24 (+0.16%) today
Markets closed · 7:59pm ET

24/7 Wall St. View

GH at a Glance

Valuation
Market cap
$19.7B
Profitability
Revenue (TTM)
$1.3B
Profit margin
-37.9%
EPS (TTM)
$-3.69
Price
52-week range
$75 – $191
Street target
$200.76
Earnings
Next report
Feb 19, 2027
Q3 2026 EPS
$-0.29
vs. $-0.31 est.
+7.8%

Headquartered in Palo Alto, CA Fiscal year ends December NASDAQ: GH guardanthealth.com

About Guardant Health

Guardant Health is a precision oncology company that develops blood- and tissue-based cancer tests, real-world data and AI analytics. Its tests are used across the cancer care continuum:
- **Screening:** the Shield blood test for colorectal cancer screening, now covered for more than 80% of eligible lives commercially.
- **Recurrence monitoring:** Guardant Reveal, including Guardant Reveal Ultra, for early-stage cancer patients.
- **Therapy selection:** Guardant360 CDx liquid biopsy and Guardant360 Tissue (PMA submitted) for patients with advanced cancer.

Guardant360 CDx holds FDA companion diagnostic approvals, including recent approvals in breast cancer for AstraZeneca's camizestrant and Lilly's imlunestrant.

The company reports revenue across four categories:
- Oncology (clinical testing)
- Biopharma & Data (services and data for pharmaceutical partners)
- Screening (Shield)
- Licensing and other Updated

Revenue by Segment · Q3 2026
  1. Oncology64%
  2. Screening19%
  3. Biopharma and Data16%
  4. Licensing and Other1%

GH Coverage

Frequently Asked Questions

What does Guardant Health do?

Guardant Health is a precision oncology company that develops blood- and tissue-based cancer tests, real-world data and AI analytics.

What is the GH stock price target?

The Wall Street consensus 12-month price target for GH is $200.76.